🚀 VC round data is live in beta, check it out!
Surgical Science Valuation Multiples
Discover revenue and EBITDA valuation multiples for Surgical Science and similar public comparables like Deltex Medical Group, Sanara MedTech, Inogen, InfuSystem and more.
Surgical Science Overview
About Surgical Science
Surgical Science Sweden AB is a supplier of virtual reality simulators for medical training. The company’s core is its proprietary software and hardware for simulating interactions between instruments and anatomy. It has two operating segments; Educational products include Proprietary brand medical simulator hardware and software for generic training of psycho-motor skills, instrument handling, and training for a large number of procedures and examinations, prior to entering the clinical environment and also support and services, and Industry/OEM includes simulation software for product-specific training of surgeons in robot-assisted surgery and other digitalized medical instruments and also simulators for medical device companies.
Founded
1999
HQ
Employees
274
Website
Financials (LTM)
EV
$112M
Surgical Science Financials
Surgical Science reported last 12-month revenue of $110M and EBITDA of $18M.
In the same LTM period, Surgical Science generated $55M in gross profit, $18M in EBITDA, and $8M in net income.
Revenue (LTM)
Surgical Science P&L
In the most recent fiscal year, Surgical Science reported revenue of $109M and EBITDA of $17M.
Surgical Science expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $110M | XXX | $109M | XXX | XXX | XXX |
| Gross Profit | $55M | XXX | $71M | XXX | XXX | XXX |
| Gross Margin | 50% | XXX | 65% | XXX | XXX | XXX |
| EBITDA | $18M | XXX | $17M | XXX | XXX | XXX |
| EBITDA Margin | 16% | XXX | 15% | XXX | XXX | XXX |
| EBIT Margin | 8% | XXX | 7% | XXX | XXX | XXX |
| Net Profit | $8M | XXX | $7M | XXX | XXX | XXX |
| Net Margin | 7% | XXX | 7% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Surgical Science Stock Performance
Surgical Science has current market cap of $178M, and enterprise value of $112M.
Market Cap Evolution
Surgical Science's stock price is $3.49.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $112M | $178M | (1.1%) | XXX | XXX | XXX | $0.14 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSurgical Science Valuation Multiples
Surgical Science trades at 1.0x EV/Revenue multiple, and 6.3x EV/EBITDA.
EV / Revenue (LTM)
Surgical Science Financial Valuation Multiples
As of March 10, 2026, Surgical Science has market cap of $178M and EV of $112M.
Equity research analysts estimate Surgical Science's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Surgical Science has a P/E ratio of 21.9x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $178M | XXX | $178M | XXX | XXX | XXX |
| EV (current) | $112M | XXX | $112M | XXX | XXX | XXX |
| EV/Revenue | 1.0x | XXX | 1.0x | XXX | XXX | XXX |
| EV/EBITDA | 6.3x | XXX | 6.7x | XXX | XXX | XXX |
| EV/EBIT | 12.9x | XXX | 14.7x | XXX | XXX | XXX |
| EV/Gross Profit | 2.0x | XXX | 1.6x | XXX | XXX | XXX |
| P/E | 21.9x | XXX | 24.1x | XXX | XXX | XXX |
| EV/FCF | 22.5x | XXX | 30.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Surgical Science Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Surgical Science Margins & Growth Rates
Surgical Science's revenue in the last 12 month grew by 3%.
Surgical Science's revenue per employee in the last FY averaged $0.4M.
Surgical Science's rule of 40 is 19% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Surgical Science's rule of X is 24% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Surgical Science Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 3% | XXX | 1% | XXX | XXX | XXX |
| EBITDA Margin | 16% | XXX | 15% | XXX | XXX | XXX |
| EBITDA Growth | 31% | XXX | 32% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 19% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 24% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 22% | XXX | 21% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 11% | XXX | 11% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 23% | XXX | 22% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 58% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Surgical Science Public Comps
See public comps and valuation multiples for other Medical Devices and VR & AR comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Deltex Medical Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Sanara MedTech | XXX | XXX | XXX | XXX | XXX | XXX |
| Inogen | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Profound Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Surgical Science M&A Activity
Surgical Science acquired XXX companies to date.
Last acquisition by Surgical Science was on XXXXXXXX, XXXXX. Surgical Science acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Surgical Science
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSurgical Science Investment Activity
Surgical Science invested in XXX companies to date.
Surgical Science made its latest investment on XXXXXXXX, XXXXX. Surgical Science invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Surgical Science
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Surgical Science
| When was Surgical Science founded? | Surgical Science was founded in 1999. |
| Where is Surgical Science headquartered? | Surgical Science is headquartered in Sweden. |
| How many employees does Surgical Science have? | As of today, Surgical Science has over 274 employees. |
| Who is the CEO of Surgical Science? | Surgical Science's CEO is Tom Englund. |
| Is Surgical Science publicly listed? | Yes, Surgical Science is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of Surgical Science? | Surgical Science trades under SUS ticker. |
| When did Surgical Science go public? | Surgical Science went public in 2017. |
| Who are competitors of Surgical Science? | Surgical Science main competitors are Deltex Medical Group, Sanara MedTech, Inogen, InfuSystem. |
| What is the current market cap of Surgical Science? | Surgical Science's current market cap is $178M. |
| What is the current revenue of Surgical Science? | Surgical Science's last 12 months revenue is $110M. |
| What is the current revenue growth of Surgical Science? | Surgical Science revenue growth (NTM/LTM) is 3%. |
| What is the current EV/Revenue multiple of Surgical Science? | Current revenue multiple of Surgical Science is 1.0x. |
| Is Surgical Science profitable? | Yes, Surgical Science is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Surgical Science? | Surgical Science's last 12 months EBITDA is $18M. |
| What is Surgical Science's EBITDA margin? | Surgical Science's last 12 months EBITDA margin is 16%. |
| What is the current EV/EBITDA multiple of Surgical Science? | Current EBITDA multiple of Surgical Science is 6.3x. |
| What is the current FCF of Surgical Science? | Surgical Science's last 12 months FCF is $5M. |
| What is Surgical Science's FCF margin? | Surgical Science's last 12 months FCF margin is 5%. |
| What is the current EV/FCF multiple of Surgical Science? | Current FCF multiple of Surgical Science is 22.5x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.